Antiseptic properties of two calix[4]arenes derivatives on the human coronavirus 229E

Antiviral Research

Volumn 88, Issue 3, 2010, Pages 343-346

  Geller, C ^a   Fontanay, S ^a   Mourer, M ^a   Dibama, H Massimba ^a   Regnouf de Vains, J B ^a   Finance, C ^a   Duval, R E ^a  

^a NANCY UNIVERSITÉ   (France)

Author keywords

1,3 Bis(bithiazolyl) tetra para sulfonato calix 4 arene; Antiseptic; HCoV 229E; Tetra para Sulfonato calix 4 arene; Virucidal

Indexed keywords

1,3 BIS(BITHIAZOLYL) TERA 4 SULFONATO CALIX[4]ARENE; CHLORHEXIDINE; HEXAMIDINE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; TETRA 4 SULFONATO CALIX[4]ARENE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONAVIRUS; DRUG CYTOTOXICITY; DRUG SCREENING; HOSPITAL INFECTION; LOWER RESPIRATORY TRACT INFECTION; NONHUMAN; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION;

ANTI-INFECTIVE AGENTS, LOCAL; BENZAMIDINES; CALIXARENES; CELL LINE; CHLORHEXIDINE; CORONAVIRUS 229E, HUMAN; CORONAVIRUS INFECTIONS; DISINFECTANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; VIRAL LOAD; VIRUS INACTIVATION;

CORONAVIRIDAE; HUMAN CORONAVIRUS 229E; TETRA;

EID: 78650248012     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.09.009     Document Type: Article

References (30)

1. Agence Française de normalisation (AFNOR) Chemical Disinfectants and Antiseptics-Virucidal Quantitative Suspension Test for Chemical Disinfectants and Antiseptics used in Human Medicine-Test Method and Requirements (phase 2, step 1) 2007, NF EN 14476+A1.
2. American Society for Testing and Material (ASTM) Standard Test Method for Efficacy of Antimicrobial Agents against Viruses in Suspension 1996, E1052-96 (last reapproval in 2002).
3. American Society for Testing and Material (ASTM) Standard Test Method for Efficacy of Virucidal Agents Intended for Inanimate Environmental Surfaces 1997, E1053-97 (last reapproval in 2002).
4. Coveney, D., Costello, B., 2005. Preparation of alkylated pyrogallol calixarene type compounds as anti-viral compounds. U.S. Patent 113,454, (2005).
5. de Fátima A., Fernandes S.A., Sabino A.A. Calixarenes as new platforms for drug design. Curr. Drug Discov. Technol. 2009, 6:151-170.
6. Falsey A.R., Walsh E.E., Hayden F.G. Rhinovirus and coronavirus infection-associated hospitalizations among older adults. J. Infect. Dis. 2002, 185:1338-1341.
7. Gagneur A., Sizun J., Vallet S., Legr M.C., Picard B., Talbot P.J. Coronavirus-related nosocomial viral respiratory infections in a neonatal and paediatric intensive care unit: a prospective study. J. Hosp. Infect. 2002, 51:59-64.
8. Geller C., Fontanay S., Finance C., Duval R.E. A new Sephadex-based method for removing microbicidal and cytotoxic residues when testing antiseptics against viruses: experiments with a human coronavirus as a model. J. Virol. Methods 2009, 159:217-226.
9. Gerna G., Campanini G., Rovida F., Percivalle E., Sarasini A., Marchi A., Baldanti F. Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients. J. Med. Virol. 2006, 78:938-949.
10. Gerna G., Percivalle E., Sarasini A., Campanini G., Piralla A., Rovida F., Genini E., Marchi A., Baldanti F. Human respiratory coronavirus HKU1 versus other coronavirus infections in Italian hospitalised patients. J. Clin. Virol. 2007, 38:244-250.
11. Harris, S.J., 1995. Calixarene-based compounds having antibacterial, antifungal, anticancer-HIV activity. WO 95/19974.
12. Harris, S.J., 2002. Preparation of Calixarenes as anti-viral compounds. WO 02/44121.
13. Hwang, K.M., Qi, Y.M., Liu, S.Y., Choy, W., 1994. Inhibition and treatment of infection by envelopped virus with calix(n)arene compounds. WO 94/03164.
14. Ijaz M.K., Brunner A.H., Sattar S.A., Nair R.C., Johnson-Lussenburg C.M. Survival characteristics of airborne human coronavirus 229E. J. Gen. Virol. 1985, 66:2743-2748.
15. Kral, V., Cigler, P., Konvalinka, J., Kozisek, M., Prejdova, J., Gruener, B., Plesek, J., Lepsik, M., Pokorna, J., Kraeusslich, H.-G., Bodem, J., 2005. Preparation and HIV protease inhibitory activity of novel mono- and dinuclear cobalt dicarbollides. WO 2005073240.
16. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J.Y., Cox N., Hughes J.M., LeDuc J.W., Bellini W.J., Anderson L.J. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348:1953-1966.
17. Lai M.Y., Cheng P.K., Lim W.W. Survival of severe acute respiratory syndrome coronavirus. Clin. Infect. Dis. 2005, 41:e67-71.
18. Larson H.E., Reed S.E., Tyrrell D.A. Isolation of rhinoviruses and coronaviruses from 38 colds in adults. J. Med. Virol. 1980, 5:221-229.
19. Laude H., Rasschaert D., Delmas B., Eleouët J.F. Le coronavirus respiratoire porcin PRCV: un virus émergent pas comme les autres. Virologie 1998, 2:305-316.
20. Li W., Shi Z., Yu M., Ren W., Smith C., Epstein J.H., Wang H., Crameri G., Hu Z., Zhang H., Zhang J., McEachern J., Field H., Daszak P., Eaton B.T., Zhang S., Wang L.F. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005, 310:676-679.
21. Motornaya A.E., Alimbarova L.M., Shokova E.A., Kovalev V.V. Synthesis and antiherpetic activity of N-(3-amino-1-adamantyl)calix[4]arenes. Pharm. Chem. J. 2006, 40:68-72.
22. Mourer M., Psychogios N., Laumond G., Aubertin A.M., Regnouf-de-Vains J.B. Synthesis and anti-HIV evaluation of water-soluble calixarene-based bithiazolyl podands. Bioorg. Med. Chem. 2010, 18:36-45.
23. Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., Nicholls J., Yee W.K., Yan W.W., Cheung M.T., Cheng V.C., Chan K.H., Tsang D.N., Yung R.W., Ng T.K., Yuen K.Y. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361:1319-1325.
24. Pene F., Merlat A., Vabret A., Rozenberg F., Buzyn A., Dreyfus F., Cariou A., Freymuth F., Lebon P. Coronavirus 229E-related pneumonia in immunocompromised patients. Clin. Infect. Dis. 2003, 37:929-932.
25. Rabenau H.F., Cinatl J., Morgenstern B., Bauer G., Preiser W., Doerr H.W. Stability and inactivation of SARS coronavirus. Med. Microbiol. Immunol. 2005, 194:1-6.
26. Rabenau H.F., Kampf G., Cinatl J., Doerr H.W. Efficacy of various disinfectants against SARS coronavirus. J. Hosp. Infect. 2005, 61:107-111.
27. Rodik R.V., Boyko V.I., Kalchenko V.I. Calixarenes in bio-medical researches. Curr. Med. Chem. 2009, 16:1630-1655.
28. Sattar S.A., Springthorpe V.S., Karim Y., Loro P. Chemical disinfection of non-porous inanimate surfaces experimentally contaminated with four human pathogenic viruses. Epidemiol. Infect. 1989, 102:493-505.
29. Sizun J., Yu M.W., Talbot P.J. Survival of human coronaviruses 229E and OC43 in suspension and after drying on surfaces: a possible source of hospital-acquired infections. J. Hosp. Infect. 2000, 46:55-60.
30. Vijgen L., Keyaerts E., Moes E., Thoelen I., Wollants E., Lemey P., Vandamme A.-M., Van Ranst M. Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J. Virol. 2005, 79:1595-1604.